Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of vinblastine III in preparing medicine for preventing or treating Alzheimer's disease

A technology for Alzheimer's disease and vinblastine, which is applied in the field of new drug development and can solve problems such as poor curative effect, toxic and side effects, etc.

Active Publication Date: 2020-01-10
陈国俊 +1
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, some of these clinically used drugs have limited their application due to their poor curative effect and some due to their toxic side effects, so it is necessary to develop new drugs for the treatment of Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of vinblastine III in preparing medicine for preventing or treating Alzheimer's disease
  • Application of vinblastine III in preparing medicine for preventing or treating Alzheimer's disease
  • Application of vinblastine III in preparing medicine for preventing or treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Cell Experiment

[0033] CNP increases the expression of ADAM10 through the NF-YB pathway

[0034] Human embryonic kidney cells HEK293, human neuroblastoma cells SH-SY5Y, and mouse hippocampal neuron cells HT22 were seeded in a 6-well plate. HEK293 cells were 2×10 per well 5 Y5Y cells 4×10 per well 5 HT22 cells 2×10 per well 5 A. The cell fusion rate of HEK293 and HT22 cells is about 60%-70%, and the cell fusion rate of Y5Y cells is about 80%-90%. After treatment for 24 hours, the concentration of the drug is 0ng / ml and 50ng / ml respectively. ,100ng / ml,200ng / mL. The experiment verified that the concentration of 100ng / mL was safe, stable and effective, and the subsequent experiments all chose 100ng / mL as the drug treatment concentration.

[0035] In order to verify the expression of transcription and protein levels, RT-PCR and Western blot (WB) experiments were performed. Specific experimental operations:

[0036] RT-PCR

[0037] RNA extraction: 1mL RNAiso Plus / well (6-...

Embodiment 2

[0071] Example 2 Animal experiment

[0072] Experimental animals: APP / PS1 transgenic mice and littermate wild-type mice used in the experiment were all derived from breeding, and their parents were purchased from the JACKSON laboratory in the United States. The mice were raised in the SPF transgenic mouse surrogate room of Chongqing Medical University. All animal feeding procedures were in accordance with the "Chinese Laboratory Animal Management Regulations." All animal experiments strictly abide by the "Animal Use Policy" promulgated by the Chinese Neuroscience Association in 1995.

[0073] experimental method

[0074] The experiment is divided into four groups: WT+CTRL, WT+CNP, AD+CNP, AD+CNP.

[0075] Conophylline (CNP for short) drug treatment method: The experimental group of 6-month-old AD mice and WT of the same age were injected intraperitoneally at the same time every other day with 1μg / KgCNP. The control group mice were given the same amount of DMSO (Dimethyl sulfoxide, di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of vinblastine III in preparing a medicine for preventing or treating Alzheimer's disease. Study found that vinblastine III (CNP) can increase the ADAM10 gene transcription and increase the expression of ADAM10 through an NF-YB way; and meanwhile, the expression of BACE1 is decreased to enable the metabolism of APP to tend to be non-amyloid way. Animal experiments show that CNP can significantly improve the spatial learning and memory abilities and hippocampal-dependent learning and memory abilities of AD model mice, so that a new idea is provided for the development of medicines for preventing or treating neurological diseases such as Alzheimer's disease.

Description

Technical field [0001] The present invention relates to the medical use of vinblastine III, in particular to the application of vinblastine III in the preparation of drugs for preventing or treating Alzheimer's disease, and belongs to the technical field of new drug development. Background technique [0002] Alzheimer disease (Alzheimer Disease, AD) is the most common Alzheimer’s disease, a progressive neurodegenerative disease with an insidious onset. It is clinically characterized by memory impairment, aphasia, apraxia, agnosia, and visual space. Comprehensive dementia, such as skill impairment, executive dysfunction, and personality and behavior changes, is characteristic, and the etiology is unknown so far. With the aging of the population, the prevalence of dementia in my country has reached 8 per 1,000 people, the incidence rate is 4%, of which more than 10 million AD patients [Reitz,C.and R.Mayeux,Alzheimer disease:epidemiology,diagnostic criteria,riskfactors and biomarker...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/475A61P25/28A61P25/16A61P25/14A61P25/08A61P25/00
CPCA61K31/475A61P25/00A61P25/08A61P25/14A61P25/16A61P25/28
Inventor 陈国俊朱炳林邓小娟胡小童王静文周贵凤查静思汤静
Owner 陈国俊
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com